³Ô¹ÏÍøÕ¾

Latest drug design News

Imugene says bile tract cancer patient maintains complete response in MAST study
Pioneering scalable hole-spin qubits for quantum computing
Statistical and computational methods for analyzing omics data and predicting drug responses
Nanoscope Therapeutics Licenses Optogenetic Technology
New advancement for development of hormone-free male contraceptive pill
PharmAust reports positive interim study results from study in ALS
Our blood-brain barrier stops bugs and toxins getting to our brain. Here’s how it works
Quantum breakthrough: World’s purest silicon brings scientists one step closer to scaling up quantum computers
Participants needed for trial of promising treatment for progressive supranuclear palsy (PSP)
Global Collaboration To Combat Chronic Lung Infection
How long before quantum computers can benefit society? That’s Google’s US$5 million question
Schneider Electric Collaborates with NVIDIA on Designs for AI Data Centres
Filament formation enables cancer cells’ glutamine addiction
Discovering the molecular recognition of technological solids by mutant self-assembling peptides
Certa Therapeutics’ FT011 granted US FDA fast track for systemic sclerosis
ISU researcher wins innovation challenge to seek RNA drug targets
QIMR Berghofer engages AI partner to fast-track cancer drug discovery
Quantum tech for health: Sydney team wins Wellcome Leap contract
US FDA grants Argenica Therapeutics’ ARG-007 orphan drug designation
Neuren Pharmaceuticals completes Phelan-McDermid syndrome Phase 2 trial 
UQ acquires world-class infrastructure with ARC support
Bourne Foundation Nuclear Magnetic Resonance (NMR) Spectroscopy Facility Official Opening
FDA grants Certa Therapeutics’ FT011 orphan drug designation for systemic sclerosis
Fellow’s ‘extraordinary journey’ leads to PM’s Science Prize
US FDA grants Orphan Drug Designation for Noxopharm’s CRO-67
Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
New discovery: dual acting drug delivers blood cancer a lethal ‘one-two’ punch
Scientists use quantum device to slow chemical process by factor of 100bn
Neuren opens first site in US for Prader-Willi syndrome Phase 2 trial
New national venture strengthens home-grown medicine outcomes
New study reveals understanding of a basic physical property of charged particles in microgravity
New study reveals understanding of basic physical property of charged particles in suspension in microgravity
“Nothing short of miraculous” – The drug offering hope to MND patients
FDA grants ‘orphan’ designation to PTX-100 for broader TCL indications
The Next Pandemic: Researchers Develop Tool to Identify Existing Drugs to Use in a Future Outbreak
NSW Government backs University-led consortium on drug discovery
Ashurst advises Perspix Biotech on market entry in AI-driven drug development
FDA approves IND for Prader-Willi syndrome study of Neuren’s NNZ-2591
EpiAxis Therapeutics and Peptilogics announce new collaboration
Future medical applications in drug design
Burnet teams up with Monash and BioCurate to develop novel HIV antivirals
New agents to combat dangerous pathogen
New orphan drug designation for Kazia Therapeutics’ paxalisib